FTO and familial pancreatic carcinoma: Having observed the overexpression of FTO in pancreatic cancer cells, we next intended to determine its role in pancreatic cancer, and hence, we employed a selective pharmacological inhibitor of FTO, CS1, which inhibit FTO’s m6A demethylase activity [34].